Halozyme Therapeutics, Inc.

DB:RV7 Stock Report

Market Cap: €5.8b

Halozyme Therapeutics Management

Management criteria checks 2/4

Halozyme Therapeutics' CEO is Helen Torley, appointed in Jan 2014, has a tenure of 10.92 years. total yearly compensation is $11.82M, comprised of 7.8% salary and 92.2% bonuses, including company stock and options. directly owns 0.52% of the company’s shares, worth €30.45M. The average tenure of the management team and the board of directors is 2.8 years and 10.9 years respectively.

Key information

Helen Torley

Chief executive officer

US$11.8m

Total compensation

CEO salary percentage7.8%
CEO tenure10.9yrs
CEO ownership0.5%
Management average tenure2.8yrs
Board average tenure10.9yrs

Recent management updates

Recent updates

CEO Compensation Analysis

How has Helen Torley's remuneration changed compared to Halozyme Therapeutics's earnings?
DateTotal CompensationSalaryCompany Earnings
Sep 30 2024n/an/a

US$392m

Jun 30 2024n/an/a

US$337m

Mar 31 2024n/an/a

US$319m

Dec 31 2023US$12mUS$920k

US$282m

Sep 30 2023n/an/a

US$254m

Jun 30 2023n/an/a

US$234m

Mar 31 2023n/an/a

US$182m

Dec 31 2022US$10mUS$872k

US$202m

Sep 30 2022n/an/a

US$211m

Jun 30 2022n/an/a

US$366m

Mar 31 2022n/an/a

US$435m

Dec 31 2021US$7mUS$830k

US$403m

Sep 30 2021n/an/a

US$409m

Jun 30 2021n/an/a

US$229m

Mar 31 2021n/an/a

US$163m

Dec 31 2020US$7mUS$791k

US$129m

Sep 30 2020n/an/a

US$22m

Jun 30 2020n/an/a

-US$40m

Mar 31 2020n/an/a

-US$80m

Dec 31 2019US$6mUS$761k

-US$72m

Sep 30 2019n/an/a

-US$40m

Jun 30 2019n/an/a

-US$43m

Mar 31 2019n/an/a

-US$51m

Dec 31 2018US$6mUS$725k

-US$80m

Sep 30 2018n/an/a

US$46m

Jun 30 2018n/an/a

US$76m

Mar 31 2018n/an/a

US$68m

Dec 31 2017US$5mUS$671k

US$63m

Compensation vs Market: Helen's total compensation ($USD11.82M) is above average for companies of similar size in the German market ($USD3.33M).

Compensation vs Earnings: Helen's compensation has increased by more than 20% in the past year.

CEO

Helen Torley (61 yo)

10.9yrs

Tenure

US$11,820,858

Compensation

Dr. Helen I. Torley, M.B. Ch. B., M.R.C.P. has been Chief Executive Officer and President of Halozyme Therapeutics, Inc. since January 6, 2014. He serves as President, CEO & Director at Halozyme, Inc. Prio...

Leadership Team

NamePositionTenureCompensationOwnership
Helen Torley
President10.9yrsUS$11.82m0.52%
€ 30.5m
Nicole LaBrosse
Senior VP & CFO2.8yrsUS$3.85m0.012%
€ 707.2k
Michael LaBarre
Senior VP & CTOno dataUS$3.24m0.14%
€ 7.9m
Mark Snyder
Senior VP & Chief Legal Officer2.9yrsUS$3.61m0.0092%
€ 533.5k
Cortney Caudill
Chief Operations Officer1.2yrsno datano data
Tram Bui
Head of Investor Relations & Corporate Communications2.9yrsno datano data
Amy Fox
Chief Human Resources Officer4.9yrsno datano data
Gary Grote
Chief Commercial Officer1.6yrsno datano data
Christopher Wahl
Chief Business Officer1.4yrsno datano data
Charles Theuer
Chief Medical Officerless than a yearno datano data

2.8yrs

Average Tenure

60yo

Average Age

Experienced Management: RV7's management team is considered experienced (2.8 years average tenure).

Board Members

NamePositionTenureCompensationOwnership
Helen Torley
President10.9yrsUS$11.82m0.52%
€ 30.5m
Connie Matsui
Independent Director18.4yrsUS$460.02k0.14%
€ 8.1m
Jeffrey Henderson
Independent Chair of the Board9.3yrsUS$555.02k0.037%
€ 2.2m
Daniel Von Hoff
Member of the Scientific Advisory Board20.3yrsno datano data
Barbara Duncan
Independent Director1.8yrsUS$528.15kno data
Jeffrey Bleil
Member of the Advisory Boardno datano datano data
Gregory Frost
Chairman of Scientific Advisory Board10.9yrsUS$68.17kno data
Gerhard Baumgartner
Member of Scientific Advisory Board20.5yrsno datano data
Sue Bailey
Member of Scientific Advisory Board19.4yrsno datano data
Matthew Posard
Independent Director11.8yrsUS$471.83k0.039%
€ 2.2m
Akiko Miyashita
Independent Director2.8yrsUS$455.02k0.011%
€ 652.0k
Bernadette Connaughton
Independent Director6.3yrsUS$470.02k0.032%
€ 1.8m

10.9yrs

Average Tenure

66yo

Average Age

Experienced Board: RV7's board of directors are seasoned and experienced ( 10.9 years average tenure).

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/26 10:06
End of Day Share Price 2024/12/23 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Halozyme Therapeutics, Inc. is covered by 34 analysts. 9 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Ishan MajumdarBaptista Research
James BirchenoughBarclays
Robert WassermanBenchmark Company